Our industry-leading RNA biology and drug discovery capabilities drive our unique approach to address targets considered “undruggable” by conventional methods: we modulate the biology of mRNAs, preventing the production of disease-driving proteins. This opens a new path to targeting the drivers of cancer and other diseases.
We are initially focused on mRNAs of undruggable proteins and RBPs linked to specific disease phenotypes. We are also using our proprietary AI/ML platform to identify high-value, clinically relevant RNA and RBP targets.